Bryce Vissel

UNSW Sydney — Australia

Neuroscience · Life Sciences

46h-index8.1kcitations145works6.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(40), Neuroinflammation and Neurodegeneration Mechanisms(29), Alzheimer's disease research and treatments(24), Epigenetics and DNA Methylation(19), Chromosomal and Genetic Variations(11)

Publications145 total

Wnt-3a exacerbates production of TNF-α in LPS stimulated microglia independent of the β-catenin canonical pathway
Scientific Reports·2026Open Access
Anti-amyloid antibodies for Alzheimer’s disease are not truly disease modifying
BMJ·2026
Renal and hepatic function is preserved following inducible knockout of kynurenine pathway enzymes KMO or QPRT in adult mice
PLoS ONE·2025Open Access
Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters
Frontiers in Pharmacology·2025Open Access
A new treatment for Huntington’s disease is genuinely promising – but here’s why we still need caution
2025
Wnt-3a exacerbates production of TNF-α in LPS stimulated microglia independent of the β-catenin canonical pathway
2025Open Access
Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer’s disease research
eLife·2024· 33 citedOpen Access
Toward the development of a sporadic model of Alzheimer's disease: comparing pathologies between humanized APP and the familial J20 mouse models
Frontiers in Aging Neuroscience·2024· 1 citedOpen Access
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Ageing Research Reviews·2024· 34 cited
Modeling sporadic Alzheimer’s disease in mice by combining Apolipoprotein E4 risk gene with environmental risk factors
Frontiers in Aging Neuroscience·2024· 6 citedOpen Access
Quantification of AMPA receptor subunits and RNA editing-related proteins in the J20 mouse model of Alzheimer’s disease by capillary western blotting
Frontiers in Molecular Neuroscience·2024· 2 citedOpen Access
Revision of Alzheimer’s diagnostic criteria or relocation of the Potemkin village
Ageing Research Reviews·2023· 8 citedOpen Access
The ratio of <scp>M1</scp> to <scp>M2</scp> microglia in the striatum determines the severity of <scp>L‐Dopa</scp> ‐induced dyskinesias
Journal of Neurochemistry·2023· 9 citedOpen Access
The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer’s disease
Molecular Neurodegeneration·2023· 31 citedOpen Access
Author response for "The ratio of &lt;scp&gt;M1&lt;/scp&gt; to &lt;scp&gt;M2&lt;/scp&gt; microglia in the striatum determines the severity of &lt;scp&gt;L‐Dopa&lt;/scp&gt;‐induced dyskinesias"
2023
Autocrine positive feedback of tumor necrosis factor from activated microglia proposed to be of widespread relevance in chronic neurological disease
Pharmacology Research & Perspectives·2023· 6 citedOpen Access
Author response for "The ratio of &lt;scp&gt;M1&lt;/scp&gt; to &lt;scp&gt;M2&lt;/scp&gt; microglia in the striatum determines the severity of &lt;scp&gt;L‐Dopa&lt;/scp&gt;‐induced dyskinesias"
2023
GluK2 Q/R editing regulates kainate receptor signaling and long-term potentiation of AMPA receptors
iScience·2023· 7 citedOpen Access
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Ageing Research Reviews·2023· 46 cited
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Journal of Alzheimer s Disease·2023· 46 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Ian A. Clark(11), Stephen F. Heinemann(11), Gary P. Morris(6), Johannes Krupp(6), Gary L. Westbrook(6), Amanda L. Wright(5), Raphael Zinn(5), Andrea Abdipranoto(5), K.H. Andy Choo(5), Michael S. Fanselow(4), Gordon A. Royle(4), Lyndsey M. Konen(3), Kasper P. Kepp(3), Nikolaos K. Robakis(3), Poul Flemming Høilund‐Carlsen(3), Stefano L. Sensi(3), Richard P. Tan(2), Sally Galbraith(2), James Daniel(2), A. Nagy(2)